EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Italian Patients Journey for Gene Therapy in Haemophilia A

Giovanni Di Minno, Gaia Spadarella, Alessandra Borchiellini, Anna Borrelli, Andrea Buzzi, Giancarlo Castaman, Michele Cecchi, Raimondo De Cristofaro, Vincenzo La Mura, Angelo Lupi, Giuseppe Malcangi, Maria Elisa Mancuso und 8 weitere

Haemophilia · 2026-11 · 32 (6) · 1397-1412

DOI: 10.1111/hae.70332 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, online erschienen am 15.06.2026. Verfasst von Giovanni Di Minno und 19 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento Di Medicina Clinica e Chirurgia, Federico II University, School of Medicine, Napoli, Italy. Hauptthemen laut MEDLINE: Hemophilia A, Genetic Therapy. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BioMarin Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Gene therapy (GT) provides sustained FVIII levels without repeated infusions in Hemophilia A (HA) patients thus overcoming a major limitation of replacement therapy. However, issues remain e.g., patient selection criteria, duration and variability of transgene expression, quality of life and long‐term safety.

Aim

This expert opinion guidance aims to define the optimal operational pathway and organizational model in Italy for the approved gene therapy (GT) product valoctocogene roxaparvovec, for patients with HA.

Methods

A multidisciplinary Working Group (healthcare professionals experienced in managing patients with HA and representatives of patients’ Associations) critically analysed the Summary of Product Characteristics (SmPC) of valoctocogene roxaparvovec and some key publications concerning GT in haemophilia. The emerging evidence, alongside with the Working Group member expertise, helped to develop this journey for Italian patients with HA treated with this AAV5‐FVIII based GT.

Results

The present journey is divided into five sections: selection and screening of eligible patients, GT prescription, GT administration and post‐infusion (short‐term [≤1 year] and long‐term [>1 year‐up to 15 years] post‐GT follow‐up). Each phase involves collaboration between centres organized in a Hub and Spoke model, adoption of Shared Decision Making (SDM) approach, multidisciplinary team working and national data collection.

Conclusion

This product‐specific operational pathway proposal provides Italian clinicians with a comprehensive framework for managing patients with HA treated with GT, acknowledging the evolving nature of this innovative therapy and the need for continuous evaluation of the proposed pathway. The present journey may need adaptation for other GT products.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AGenetic TherapyHumansItalyFactor VIIIGene Therapy AgentsQuality of Life

Stichwörter der Autor:innen

decision makinggene therapyhaemophilia Amodelsorganizationalpatient pathwayshared

Substanzen

Factor VIII

Autor:innen und Institutionen

  • Dipartimento Di Medicina Clinica e Chirurgia, Federico II University, School of Medicine, Napoli, Italy.
  • Dipartimento Di Scienze Biomediche Avanzate, Federico II University, School of Medicine, Napoli, Italy.
  • Regional Centre For Hemorrhagic and Thrombotic Diseases, Hematology Unit AOU Città della Salute e della Scienza, Turin, Italy.
  • Direzione Sanitaria, AOU "Federico II", Napoli, Italy.
  • Fondazione Paracelso, Milano, Italy.
  • Center For Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy.

Förderung

  • BioMarin Pharmaceutical

Zitieren

APA

Di Minno, G., Spadarella, G., Borchiellini, A., Borrelli, A., Buzzi, A., Castaman, G., Cecchi, M., De Cristofaro, R., La Mura, V., Lupi, A., Malcangi, G., Mancuso, M. E., Mansueto, M. F., Santoro, C., Santoro, R. C., Solimeno, L. P., Tagliaferri, A., Zanon, E., Garagiola, I., & Peyvandi, F. (2026). Italian Patients Journey for Gene Therapy in Haemophilia A. Haemophilia, 32(6), 1397-1412. https://doi.org/10.1111/hae.70332

Vancouver

Di Minno G, Spadarella G, Borchiellini A, Borrelli A, Buzzi A, Castaman G, et al. Italian Patients Journey for Gene Therapy in Haemophilia A. Haemophilia. 2026;32(6):1397-1412. doi:10.1111/hae.70332

BibTeX
@article{DiMinno2026,
  author = {Di Minno, Giovanni and Spadarella, Gaia and Borchiellini, Alessandra and Borrelli, Anna and Buzzi, Andrea and Castaman, Giancarlo and Cecchi, Michele and De Cristofaro, Raimondo and La Mura, Vincenzo and Lupi, Angelo and Malcangi, Giuseppe and Mancuso, Maria Elisa and Mansueto, Maria Francesca and Santoro, Cristina and Santoro, Rita Carlotta and Solimeno, Luigi Piero and Tagliaferri, Annarita and Zanon, Ezio and Garagiola, Isabella and Peyvandi, Flora},
  title = {Italian Patients Journey for Gene Therapy in Haemophilia A},
  journal = {Haemophilia},
  year = {2026},
  volume = {32},
  number = {6},
  pages = {1397--1412},
  doi = {10.1111/hae.70332}
}
Kostenlos starten →